Evidence map›Paper›PMID 31912605›Full record

Trial reportEuropean journal of heart failure2020

Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).

Kevin Damman, Joost C Beusekamp, Eva M Boorsma, Henk P Swart, Tom D J Smilde, Arif Elvan, J W Martijn van Eck, Hiddo J L Heerspink, Adriaan A Voors

2 registry-linked trialsOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 209 papers, 32 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
209citing papers in PubMed, 32 pooled it
39.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05457933 phase4completedstarted 2022, after this paper: background citation

Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes: a Prospective, Open-label, Non-inferiority Randomized Trial

Ran2022Enrolled250Registered outcomes17Posted comparisons0ConditionsCoronary Artery Disease, Type2DiabetesArmsdapagliflozin, Glargine
PMID 33515493other papers from this trial
Open the trial in the graph
NCT06012279 phase4completedstarted 2023, after this paper: background citation

Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction, a Randomized Controlled Trial (CODA-HFrEF)

Ran2023Enrolled117Registered outcomes8Posted comparisons0ConditionsAcute Heart FailureArmsDapagliflozin 10mg Tab
PMID 31535829PMID 36553880other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

209 citing papers in PubMed, 32 syntheses or guidelines pooled it, 433 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Guideline
  18. Pooled it
  19. Right Heart Function in Cardiorenal Syndrome.Current heart failure reports · 2022
    Pooled it
  20. Pooled it

149 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Kevin DammanUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Joost C BeusekampUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Eva M BoorsmaUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Henk P SwartAntonius Ziekenhuis Sneek, Sneek, The Netherlands.
Tom D J SmildeTREANT zorggroep, Emmen, The Netherlands.
Arif ElvanDepartment of Cardiology, ISALA, Zwolle, The Netherlands.
J W Martijn van EckJeroen Bosch Ziekenhuis, Den Bosch, The Netherlands.
Hiddo J L HeerspinkUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Adriaan A VoorsUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
University Medical Center Groningen · NLIsala · NLJeroen Bosch Ziekenhuis · NLSt. Antonius Ziekenhuis · NLThe George Institute for Global Health · AUTreant Zorggroep · NL

Funding

Boehringer Ingelheim
6 · The paper itself

Abstract

aimsInhibition of sodium-glucose co-transporter 2 (SGLT2) reduces the risk of death and heart failure (HF) admissions in patients with chronic HF. However, safety and clinical efficacy of SGLT2 inhibitors in patients with acute decompensated HF are unknown. METHODS AND

resultsIn this randomized, placebo-controlled, double-blind, parallel group, multicentre pilot study, we randomized 80 acute HF patients with and without diabetes to either empagliflozin 10 mg/day or placebo for 30 days. The primary outcomes were change in visual analogue scale (VAS) dyspnoea score, diuretic response (weight change per 40 mg furosemide), change in N-terminal pro brain natriuretic peptide (NT-proBNP), and length of stay. Secondary outcomes included safety and clinical endpoints. Mean age was 76 years, 33% were female, 47% had de novo HF and median NT-proBNP was 5236 pg/mL. No difference was observed in VAS dyspnoea score, diuretic response, length of stay, or change in NT-proBNP between empagliflozin and placebo. Empagliflozin reduced a combined endpoint of in-hospital worsening HF, rehospitalization for HF or death at 60 days compared with placebo [4 (10%) vs. 13 (33%); P = 0.014]. Urinary output up until day 4 was significantly greater with empagliflozin vs. placebo [difference 3449 (95% confidence interval 578-6321) mL; P < 0.01]. Empagliflozin was safe, well tolerated, and had no adverse effects on blood pressure or renal function.

conclusionsIn patients with acute HF, treatment with empagliflozin had no effect on change in VAS dyspnoea, diuretic response, NT-proBNP, and length of hospital stay, but was safe, increased urinary output and reduced a combined endpoint of worsening HF, rehospitalization for HF or death at 60 days.

Indexed as

Heart FailureAgedBenzhydryl CompoundsDouble-Blind MethodFemaleGlucosidesHumansMaleNatriuretic Peptide, BrainPeptide FragmentsPilot ProjectsTreatment OutcomeBenzhydryl CompoundsempagliflozinGlucosidesNatriuretic Peptide, BrainPeptide FragmentsAcute heart failureBlood pressureDiuresisDyspnoeaEmpagliflozinHospital readmissionRenal functionSodium-glucose co-transporter 2

Identifiers

PMID31912605
OpenAlexW3000647500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.